| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_846e66e8b612cd7b513a9483826b4f15
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_46774b47ad95a43cfcb84ed43352f454
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2514ba10f5799fcdbfc53f8ed02c0709
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a218d20f2755007f860fde0e817d66e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a85eac2a3f942904b625fe73feacc76a |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2319-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-6068
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0011
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-0005
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-55 |
| filingDate |
2005-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56f0ba22c1ea7adbf483ffc3fdefc716
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e402f108cb5798758fb74bb0955b43b9
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_017e1006a58003fea5c3483c7b622f69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_327d92bdb9c5e886b60b8dec14b19f14 |
| publicationDate |
2006-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2006053508-A1 |
| titleOfInvention |
Immunotherapeutic formulations with interleukin-2-neutralising capacity |
| abstract |
The invention relates to pharmaceutical formulations which can be used in relation to cancer and which block the binding of Interleukin 2 (IL-2) to the receptor thereof. More specifically, the invention relates to therapeutic formulations that can increase the immunogenicity of IL-2 by coupling same to transport protein P64k of Neisseria meningitidis in adjuvant Montanide ISA 51 for the induction of autoantibodies that block the binding of IL-2 to the receptor thereof. The invention also relates to effective methods for the treatment of tumours, including breast cancer. The invention further relates to the therapeutic combination of the IL-2-based vaccine with other cancer vaccines based on specific antigens of tumours or tumour growth factors, as well as radiotherapy or chemotherapeutic medicaments that are traditionally used in oncological practice. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2013100297-A |
| priorityDate |
2004-11-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |